Exciting new information from the PROCLIPI study shows that POTELIGEO (mogamulizumab) can help people with advanced skin lymphoma (CTCL) live longer. This news was shared at a big meeting in Athens. The PROCLIPI study is one of the largest of its kind, with over 2,000 patients from 19 countries. It’s helping doctors understand and predict how different types of skin lymphoma, like mycosis fungoides (MF) and Sézary syndrome (SS), will progress. In the study, 371 patients with advanced MF and SS were looked at. Those who took mogamulizumab lived a median of 64 months, while those who didn’t take it lived a median of 54 months. For a group of 96 SS patients, those who took mogamulizumab lived around 6.5 years, while those who didn’t lived around 3 years. Professor Julia Scarisbrick, who led the study, said, ‘The PROCLIPI Study shows how important it is to work together globally when studying rare diseases. By combining data from all over the world, we can learn things that we couldn’t learn alone.’ Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, said, ‘For those of us dealing with CTCL, living longer isn’t just about numbers. It’s about spending more time with family, planning for the future, and living life with dignity.’ Dr Nick Kronfeld, from Kyowa Kirin International, said, ‘This news about improved survival for CTCL patients is a big step forward. It gives us stronger proof that this treatment works and shows the value of international teamwork in rare disease research.’